Selected Examples of Topics and Questions from Previous KOL ACCESS INTERVIEWS

These samples have been redacted to maintain client confidentiality, and, to not reveal our proprietary techniques that we use with KOLs to provide detailed product and competitive information.

SAMPLE TOPIC #1: Checkpoint Inhibitors Used for Non-Small Cell Lung Cancer

EXAMPLE INTERVIEW QUESTIONS:

  • What are the most important emerging agents for Advanced Stage or Metastatic NSCLC? Can you name them and briefly explain why you cite them? NOTE TO READERS: This question is extremely important. The hierarchy and order of listing the checkpoint inhibitors is important to how he/she sees them versus each other? Where would your checkpoint inhibitor fit? What would happen if your drug was NOT mentioned? It actually happens sometimes that your drug is not even mentioned by a KOL who is already on your Traditional Advisory Board!
  • What is your personal first-line choice for Advanced Stage or Metastatic NSCLC patients with the following characteristics? (To be listed). Why? Please elaborate.
  • Do you ever consider other first-line choices for Advanced Stage or Metastatic NSCLC patients? Why? Please elaborate.
  • How do you decide among the several different FDA-approved checkpoint inhibitor options for treating Advanced Stage or Metastatic NSCLC patients? Please be as detailed as possible.
  • How important is Tumor Mutation Burden (TMB) to you in selecting checkpoint inhibition for Advanced Stage or Metastatic NSCLC patients? Why? How and when do you use TMB? Do you consider TMB as a standard of care? Why? Why not?
  • If a test result reveals a low TMB, can you/or do you consider starting checkpoint inhibition therapy? or do you start with chemotherapy only? Why? And When?
  • Do you use immune therapy for NSCLC patients who have a history of auto-immune diseases ranging from non-life-threatening rheumatoid arthritis to pneumonitis? When? Why?
  • Do you initiate checkpoint inhibition as MONO or COMBINATION therapy for treatment-naïve Advanced Stage or Metastatic NSCLC patients? Which and Why?
  • How long do you continue checkpoint inhibition in responding patients? Do you ever temporarily suspend treatment for a patient with stable disease? Do you retreat with the same or another checkpoint inhibitor upon relapse?
  • Do you use only checkpoint inhibitors that have FDA-approved labelling for Stage 3 NSCLC?
  • Etc.

SAMPLE TOPIC #2: Initial Therapy for Small Cell Lung Cancer

EXAMPLE INTERVIEW QUESTIONS:

  • What is your personal first choice for Extensive Disease SCLC patients with the following characteristics? (To be listed). Why? Please elaborate.
  • Do you use maintenance therapy or SCLC? If yes. Why? What? If not, Why not?
  • Do you initiate checkpoint inhibition as MONO or COMBINATION therapy for treatment-naïve Extensive Disease SCLC patients? Which drug(s) and Why?
  • What drug(s) do you use for initial therapy in Limited Disease SCLC patients? and Why?
  • In the absence of FDA approved indications for relapsed/refractory SCLC, what is the impact on second-line therapy for SCLC of the 2018 NCCN Guidelines that list three checkpoint inhibitors/regimens for second-line SCLC therapy after chemotherapy? Why?
  • Do you believe that checkpoint inhibition will become adopted soon for second-line? Or will oncologists wait for FDA approvals in the second line with checkpoint inhibition? Why?
  • What are the most important emerging agents for SCLC therapy? Can you name them and briefly explain why you cite them here? Which do you believe is the most exciting? Why?
  • Do you think that any of the drugs for SCLC in clinical trials will prove to be failures? If yes, Which one(s)? Why?